These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 15358012)

  • 21. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between antihypertensive combination therapies comprising diuretics and/or beta-blockers and the risk of new-onset diabetes: a retrospective longitudinal cohort study.
    Liou YS; Ma T; Tien L; Lin CM; Jong GP
    Hypertens Res; 2009 Jun; 32(6):496-9. PubMed ID: 19390541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-blockers, diabetes, and hypoglycemia: risky business?
    Levinson PD
    Med Health R I; 2001 Mar; 84(3):81-2. PubMed ID: 11280134
    [No Abstract]   [Full Text] [Related]  

  • 24. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Medical treatment of hypertension--what treatment for what patients?].
    Zidek W; Tepel M; van der Giet M
    MMW Fortschr Med; 2004 May; 146(22):31-4. PubMed ID: 15373106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hypertension therapies compared. Are the new nevertheless better than the old?].
    MMW Fortschr Med; 2005 Mar; 147(12):6, 8. PubMed ID: 15832780
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
    Andraws R; Brown DL
    Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renin-angiotensin-system blockade in the prevention of diabetes.
    Ostergren J
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular drug therapy in the elderly.
    Aronow WS; Frishman WH; Cheng-Lai A
    Cardiol Rev; 2007; 15(4):195-215. PubMed ID: 17575484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antihypertensive medications and risk of diabetes mellitus.
    Barzilay JI; Cutler JA; Davis BR
    Curr Opin Nephrol Hypertens; 2007 May; 16(3):256-60. PubMed ID: 17420670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential oral manifestations of cardiovascular drugs.
    Habbab KM; Moles DR; Porter SR
    Oral Dis; 2010 Nov; 16(8):769-73. PubMed ID: 20604876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up.
    Almgren T; Wilhelmsen L; Samuelsson O; Himmelmann A; Rosengren A; Andersson OK
    J Hypertens; 2007 Jun; 25(6):1311-7. PubMed ID: 17563546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The metabolic syndrome in hypertension: European society of hypertension position statement.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
    J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An approach to heart failure and diabetes mellitus.
    Fonarow GC
    Am J Cardiol; 2005 Aug; 96(4A):47E-52E. PubMed ID: 16098844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Vascular agents can prevent type 2 diabetes].
    Nilsson P
    Lakartidningen; 2003 Feb; 100(7):528-30. PubMed ID: 12640987
    [No Abstract]   [Full Text] [Related]  

  • 38. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Revised guidelines for antihypertensive treatment. What is relevant for the general practitioner?].
    Zidek W
    MMW Fortschr Med; 2004 Jan; 146(1-2):37-8. PubMed ID: 18437867
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacological treatment for myocardial infarction Part 2: Implications of clinical trials of other adjunctive therapies.
    Avezum A; Pais P; Flather MD; Anand S; Yusuf S
    Indian Heart J; 1995; 47(2):95-105. PubMed ID: 7590849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.